in increased AGE levels. The receptor for AGE (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules present on multiple cell types, usually expressed at low levels in homeostasis and to increased degrees in diabetic tissues and at sites of stress or injury. Increased accumulation of AGEs and enhanced activation of RAGE contribute to the pathogenesis of diabetic complications. [10] [11] [12] [13] [14] [15] In human subjects, RAGE is highly expressed in peripheral occlusive vascular disease lesions. 16 In experimental models, earlier studies showed that RAGE plays central roles in the injury response to global hypoxia and ischemia/reperfusion injury. [17] [18] [19] [20] Here, we hypothesized that deficiency of Ager (gene encoding RAGE) or overexpression of Glo1 in hindlimb ischemia would restore blood flow recovery and angiogenesis in diabetic mice. To address this concept, we used a wellestablished mouse model of hindlimb ischemia (a preclinical model of PAD) 21 to assess the role of RAGE in both the immediate response to ischemic stress and the long-term effects of this receptor on tissue remodeling and angiogenesis in both the nondiabetic and diabetic states. In addition, we explored the role of RAGE ligands, AGEs, by examining the impact of overexpression of Glo1 22 in mice undergoing hindlimb ischemia, and we probed the underlying mechanisms using in vivo, ex vivo, and in vitro analyses of peripheral blood and muscle tissues. Collectively, our data reveal that the AGE-RAGE axis blunts angiogenesis and blood flow recovery, at least in part, through an impingement on adaptive immune and vascular cell responses consequent to hindlimb ischemia, which may be restored by deletion of Ager or overexpression of Glo1. These data contribute to an emerging paradigm in which RAGE condition-dependent pro-versus anti-inflammatory responses may prevail depending on the unique stress and distinct cues within the discrete microenvironment.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

RAGE Impairs Blood Flow Recovery and Angiogenesis After Hindlimb Ischemia
To establish whether RAGE modulates responses to hindlimb ischemia, we began by detecting RAGE expression in the leg muscles of streptozotocin-induced diabetic and nondiabetic wild-type (WT) mice on day 5 after femoral artery ligation (FAL). RAGE protein was significantly higher in the ischemic muscles of diabetic WT mice compared with nonischemic muscles of diabetic WT mice (P<0.0001; Figure 1A) . A significant increase in RAGE protein was also observed in the ischemic muscles of nondiabetic WT mice compared with the nonischemic muscles of nondiabetic WT mice (P<0.05; Figure 1A ). Furthermore, the expression of RAGE protein in the ischemic muscles of diabetic WT mice was significantly higher than that observed in the ischemic muscle of nondiabetic WT mice (P<0.01; Figure 1A ). These observations indicate that hindlimb ischemia induced increased expression of RAGE in ischemic muscles, especially in diabetic WT mice, and suggested potential roles for RAGE in the response to hindlimb ischemia. To address this premise, we tested the effect of deletion of Ager on vascular repair responses in the presence or absence of DM.
We performed FAL and began by assessing the role of RAGE in blood flow recovery. Laser Doppler perfusion imaging revealed that restoration of perfusion was significantly lower in diabetic WT mice compared with nondiabetic WT mice on day 28 after FAL (P<0.05; Figure 1B ). In contrast, significantly higher blood flow was observed in both diabetic and nondiabetic Ager −/− mice compared with their respective controls 28 days after FAL (P<0.01; Figure 1B ). Of note, induction of DM by streptozotocin resulted in expected rises in the levels of blood glucose, and there were no differences based on Ager genotype (Table I in the online-only Data Supplement) .
To assess the effects of DM and RAGE on angiogenesis in response to hindlimb ischemia, histological assessment of capillary density was performed in WT mice and in mice devoid of Ager on day 28 post-FAL. As shown in Figure 1C , diabetic WT mice displayed significantly lower capillary density than nondiabetic mice on day 28 postligation (P<0.01). In contrast, mice devoid of Ager displayed significantly higher capillary density on day 28 in both the nondiabetic and diabetic states versus respective WT mice (P<0.05 and P<0.01; Figure 1C ). 
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RAGE Impairs Gene Expression of Inflammatory and Angiogenic Mediators and Macrophage Infiltration After Hindlimb Ischemia, Especially in Diabetic Mice
Prompted by these observations, we sought to identify the genes impacted by DM and RAGE in hindlimb ischemia, and we profiled genes essential to angiogenesis using a commercial angiogenesis RT2 profiler polymerase chain reaction (PCR) array. Among the 84 genes tested, Tables II, III , and IV in the online-only Data Supplement illustrate some of the findings on skeletal muscle RNA of WT and Ager −/− mice on day 3, 5, and 7 after FAL in the absence and presence of DM compared with that of nondiabetic WT-sham controls. A significant theme that emerged from this analysis was that prominent gene expression changes related to inflammation were observed among the groups, and that these changes were driven, at least in part, by RAGE. After FAL, particularly in nondiabetic and diabetic Ager −/− mice, marked increases in chemokines, inflammatory, and matrix metalloproteinase genes were observed compared with nondiabetic and diabetic WT mice. Levels of key chemokine (Ccl2 [che-
, and Cxcl5 [Ena-78]) remain elevated in Ager −/− mice versus respective WT mice in the nondiabetic and diabetic states on day 7, as well as on days 3 and 5. At the later time point, day 7, higher expression of growth and proangiogenic factors was observed in Ager −/− versus WT mice in both the diabetic and nondiabetic states. Transcripts for Angpt2 (angiopoietin-2), Hgf (hepatocyte growth factor), Mdk (midkine), Pgf (placental growth factor), Sphk1 (sphingosine kinase), Tgfb (transforming growth factor beta), and Thbs1 (thrombospondin-1) were higher in Ager −/− ischemic tissues. Although we did not observe any differences in Hif1 (hypoxia-inducible factor-1)α mRNA transcripts on days 3 and 5, on day 7, the Ager −/− groups displayed higher levels of Hif1α mRNA transcripts versus the WT groups. Levels of Itgβ3 (Integrin β chain, β3 precursor) and Pecam1/Cd31 (platelet/endothelial cell adhesion molecule-1) transcripts were higher in both groups of Ager −/− mice on day 7. Note that no significant differences in Vegf a, b, or c (vascular endothelial growth factor) were observed by DM status or by the expression or not of Ager.
We performed real-time quantitative PCR to confirm the key findings and focused on inflammatory genes given the striking increase in the Ager-deficient tissues versus the WT and the profound importance of inflammatory mechanisms in facilitating vascular and tissue repair after FAL. We found that in the ischemic muscle tissue, significantly lower levels of Ccl2 mRNA transcripts were observed in WT diabetic mice versus nondiabetic WT mice on day 7 postligation (P<0.001; Figure 2A ). In mice devoid of Ager, higher Ccl2 transcripts versus WT mice on day 7 were observed in the skeletal muscle tissue in both the nondiabetic and diabetic states after FAL (P<0.001; Figure 2A ). These data suggest that RAGE suppresses chemokine gene expression in the microenvironment of hindlimb ischemia.
Based on our previous findings that Egr1 (early growth response gene-1) is a principal regulator of Ccl2 in hypoxia/ ischemia, 17, 23 we assessed Egr1 mRNA in the ischemic muscles versus sham. Compared with WT nondiabetic mice, levels of Egr1 mRNA transcripts were significantly lower in diabetic WT mice muscle tissues on day 5 postligation (P<0.05; Figure 2B ). Moreover, Egr1 mRNA transcripts on day 5 postligation were significantly higher in Ager −/− versus respective WT mice in the absence and presence of DM (P<0.001; Figure 2B ). However, by day 28 postligation, mRNA levels of Egr1 and Ccl2 were overall much lower in both WT and Ager −/− mice, in the nondiabetic and diabetic states and in sham versus ischemia, thereby indicating that the expression of mediators linked to the inflammatory response was significantly attenuated in all groups by this time point ( Figure I in the online-only Data Supplement). Collectively, these data suggest that RAGE attenuates hypoxia/ischemiadependent inflammation and mechanisms to recruit immune cells in response to hindlimb ischemia.
CCL2 has been recognized as one of the key chemokines that regulates migration and infiltration of monocytes/macrophages, 24 and macrophages have been recognized as critical regulators of angiogenesis. [25] [26] [27] We, thus, evaluated the numbers of infiltrating macrophages into the ischemic muscle on day 7 post-FAL by quantifying CD68+ macrophages in this tissue. In line with gene expression data in the muscle tissue, diabetic ischemic muscle tissue displayed lower numbers of CD68+ macrophages per unit area compared with nondiabetic tissue in WT mice (P<0.05; Figure 2C ). However, deficiency of Ager in the nondiabetic and especially diabetic ischemic muscles resulted in significantly higher numbers of CD68+ cells/unit area compared with that observed in respective WT mice (P<0.05 and P<0.01, respectively; Figure 2C ). These data suggest that RAGE reduces macrophage content in ischemic muscle, in parallel with impaired angiogenesis and blood flow recovery.
AGEs Are Increased in Diabetic, Ischemic Tissue
We next sought to identify putative RAGE ligands accounting for these effects in the ischemic muscles of diabetic and nondiabetic WT mice by using an antibody against carboxymethyl lysine (CML), one of the major structures of AGEs highly prevalent in vivo. Two key patterns were evident from the results of this experiment; first, a significant increase in CML-modified protein was noted in WT diabetic muscle sham tissues at baseline compared with nondiabetic WT mice (P<0.001; Figure 3A ). Second, in WT nondiabetic or diabetic mice, hindlimb ischemia itself resulted in a significant increase in CML-modified protein in muscle tissue versus sham treatment (P<0.01 and P<0.05, respectively; Figure 3A ). Because glyoxalase-1 (GLO1) is a principal detoxifying enzyme for AGE precursor methylglyoxal controlling AGE levels, we tested the levels of Glo1 gene expression in hindlimb muscle tissues. Levels of Glo1 mRNA were significantly reduced by FAL in hindlimb ischemia versus sham treatments in both the nondiabetic and diabetic states (P<0.05 in both cases; Figure 3B ) but were significantly higher in respective Ager-deficient tissue at baseline and on day 3 postligation compared with WT tissue in both the nondiabetic and diabetic states (P<0.05 in both cases; Figure 3B ). Western blotting revealed no statistically significant differences in levels of GLO1 protein in the muscle tissues among these groups of mice ( Figure IIA in the online-only Data Supplement).
Because it is established that AGEs are generated in DM, hypoxia/reoxygenation, and ischemia/reperfusion injury, 17, 20 we measured levels of CML protein in the ischemic and nonischemic muscle tissues of diabetic and nondiabetic transgenic mice overexpressing Glo1. We found that levels of CML-modified protein were significantly lower in transgenic (Glo1) mice compared with respective WT mice on day 5 postligation in DM (P<0.05; Figure 3A ) and at baseline in the diabetic state (P<0.05; Figure 3A ), although the levels of CML-modified protein were undetectable at baseline in both nondiabetic WT and transgenic (Glo1) mice ( Figure 3A ). These data validated that transgenic mice expressing Glo1 reduced AGE content in the muscle tissue, especially in DM and post-FAL and provided a key strategy to test the premise that AGEs contributed mechanistically to impaired angiogenesis and blood flow recovery in FAL.
Finally, we examined the levels of a distinct RAGE ligand, S100B, in the skeletal muscle of the mice under study. No significant differences were observed among any of the mouse groups when considering surgical condition, DM versus nondiabetes or genotype ( Figure IIB in the online-only Data Supplement). These data suggested that the AGE ligands, not S100B, were more likely to contribute to the RAGE-dependent effects in both nondiabetic and diabetic hindlimb ischemia.
Overexpression of Glo1 Restores Diabetes-and Ischemia-Induced Impairment of Blood Flow Recovery, Angiogenesis, Macrophage Infiltration, and Inflammatory Mediator Gene Expression
Because our data suggested that both DM and ischemia increased AGE levels, we tested the hypothesis that transgenic overexpression of Glo1 would rescue FAL-subjected mice from suppression of angiogenesis, blood flow recovery, and inflammation in ischemic muscle tissue, especially in DM. Laser Doppler blood flow analyses showed significantly higher ischemic/sham limb blood flow ratio in both sets of transgenic (Glo1) mice (nondiabetic and diabetic condition), compared with their respective WT controls on day 28 postligation (P<0.01 and P<0.001, respectively; Figure 4A ). Consistent with this observation, transgenic (Glo1) mice displayed significantly higher capillary density in both the nondiabetic and diabetic states compared with WT mice on day 28 postligation (P<0.05 and P<0.01, respectively; Figure 4B ). We measured gene expression of inflammatory mediators in the muscle tissue using real-time PCR analysis. Our data reveal that significantly higher Ccl2 (P<0.05 and P<0.001; Figure 4C ) and Egr1 (P<0.001 in both cases; Figure 4D ) transcripts in the skeletal muscle tissue of transgenic (Glo1) versus WT mice on day 5 after FAL were noted in both the nondiabetic and diabetic states. These data indicate that reduction of RAGE ligand AGEs by overexpression of Glo1 restored adaptive inflammatory gene expression in the microenvironment of hindlimb ischemia.
Effects of High Glucose on Gene Expression of Inflammatory Mediators From Ageror Glo1-Modified Macrophages
Based on the observation of increased macrophage content in the ischemic muscle tissues of Ager −/− mice compared with WT mice, especially in DM, the inflammatory gene expression of macrophages under high glucose (HG) conditions was studied using bone marrow-derived macrophages Figure 5A ) and Egr1 (P<0.0001; Figure 5B ) transcription was significantly higher in Ager −/− or Glo1 overexpressing BMDMs compared with WT BMDMs.
We extended the time course to 7 days to test whether the effects of HG were sustained and whether the impact of HG condition was RAGE-dependent. BMDMs were cultured in LG or HG, and real-time quantitative PCR was performed to detect mRNA transcripts for pro-and anti-inflammatory genes. Levels of Egr1 mRNA were significantly higher in 
Effect of RAGE on HG-Induced Macrophage/ Endothelial Interaction and Monocyte Inflammation
These data led us to probe the role of RAGE in macrophageendothelial interactions and in monocyte inflammation, 2 key factors in the response to tissue injury. We began by investigating whether HG conditions modulated the interaction of macrophages with the endothelium and probed the potential role of RAGE by determining the adhesion of fluorescentlylabeled WT or Ager −/− BMDMs to WT or Ager −/− mouse aortic 
endothelial cell (MAEC) monolayers, respectively, under
LG or HG conditions. Under LG condition, no significant Ager genotype-dependent differences in the adhesion ability of BMDMs to MAEC monolayers were noted ( Figure 6A ). In contrast, when both cell types were cultured in HG, WT BMDM adhesion to WT MAECs was significantly lower compared with that observed in cells cultured in LG (P<0.05; Figure 6A ). However, in HG, significantly higher adhesion of Ager −/− BMDMs to WT MAECs and to Ager −/− MAECs was observed compared with the adhesion of WT BMDMs to WT MAECs or Ager −/− MAECs (P<0.001 and P<0.0001; Figure 6A ). Taken together, these data indicate that HG mediates reduced WT BMDM adhesion to MAECs and that deletion of Ager, particularly in BMDMs, or BMDMs and MAECs, but not MAECs alone, rescued the suppressive effects of HG on BMDM-MAEC adhesion. These data suggested that deletion of Ager, especially in the HG state, increased BMDM interaction with ECs.
To address the underlying mechanisms, we first tested circulating levels of MCP1 (monocyte chemoattractant protein-1); MCP1 is the protein product of the Ccl2 gene. Although in diabetic WT mice, significantly higher baseline levels were observed compared with nondiabetic mice (P<0.01; Figure  IV in the online-only Data Supplement); no increases were noted at day 7 or 28 days after FAL in the mice devoid of Ager ( Figure IV in the online-only Data Supplement). In fact, no significant differences were noted at any time point or condition in the mice devoid of Ager. These findings suggested that cell-specific factors, not circulating mediators, might account for the significant functional differences observed in WT or mice devoid of Ager after hindlimb ischemia. Hence, we examined the Ly6C hi and Ly6C lo monocyte and neutrophil populations.
Prompted by our finding that higher levels of CD68+ macrophages were noted in diabetic or nondiabetic ischemic tissues in mice devoid of Ager versus the WT controls ( Figure 2C ), we obtained peripheral blood from the mice under study at baseline (day 0), 7, or 28 days after FAL and examined monocyte populations, including Ly6C We examined the total monocytes across the entire time course and within each genotype as well. In the WT mice during the time course and nondiabetic and diabetic conditions, there were no significant differences in total monocytes in any of the groups ( Figure 6B ). In contrast, in the Ager −/− mice, total monocytes were significantly higher in diabetic versus nondiabetic mice at baseline (P<0.01), and total monocytes were significantly higher on day 28 in diabetic versus nondiabetic mice devoid of Ager (P<0.0001). Finally, total monocytes were significantly higher in diabetic Ager −/− mice on day 28 versus day 7 (P<0.01; Figure 6C ).
Next, we examined the monocyte subsets. First, in the WT mice at baseline, the %Ly6C hi cells were significantly higher in the diabetic versus nondiabetic mice (P<0.01; Figure 6B ). In nondiabetic WT mice, there were no significant differences in %Ly6C hi or Ly6C lo monocytes comparing baseline with day 7 or day 28 after FAL ( Figure 6B ). In the diabetic state, significantly lower %Ly6C hi and %Ly6C lo monocytes were observed at day 7 versus baseline (P<0.01 and P<0.05, respectively; Figure 6B ). By day 28 in the diabetic WT mice, only the %Ly6C lo not the %Ly6C hi population was significantly higher compared with the levels observed at day 7 (P<0.05; Figure 6B ). In Ager −/− mice, surprisingly, we found that significantly higher %Ly6C hi monocytes were observed at baseline in the diabetic versus the nondiabetic mice devoid of Ager (P<0.0001; Figure 6C ). The %Ly6C hi population was significantly lower in the diabetic Ager −/− mice on day 7 versus diabetic baseline (P<0.01; Figure 6C ), and unlike in the diabetic WT mice, this population had significantly recovered by day 28 (compared with day 7) in the diabetic Ager −/− mice (P<0.01; Figure 6C ). In the Ager −/− mice, there were no statistically significant differences in the proportion of Ly6C lo cells at any time point or condition ( Figure 6C ).
Finally, we examined blood neutrophil content at baseline and found that the only significant difference was in the nondiabetic state, in which nondiabetic Ager −/− mice displayed significantly lower neutrophil content versus the WT mice (P<0.01; Figure VA and VC in the online-only Data Supplement). In contrast, no genotype differences were observed in the diabetic state, thereby strongly suggesting that differences in neutrophils likely did not contribute to Agerdependent effects in the response to hindlimb ischemia.
Taken together, these data revealed that significant and surprising patterns emerged in the total monocytes and Ly6C monocyte subsets with respect to RAGE expression as follows: (1) total monocytes and Ly6C hi monocytes were significantly higher at baseline in diabetic versus nondiabetic Ager −/− mice, indicating that deletion of Ager not only did not attenuate this inflammatory response, but enhanced it in DM; and (2) the %Ly6C hi cells significantly recovered by day 28 versus day 7 post-FAL only in diabetic mice devoid of Ager but not in the WT mice, in parallel with improved blood flow recovery and angiogenesis on day 28.
Discussion
Enhancement of angiogenesis and the resulting improvement of limb blood flow are the key restorative mechanisms in response to ischemia. [28] [29] [30] However, the impairment of physiological angiogenesis has been implicated in exacerbation of peripheral limb ischemia, especially in DM, but the underlying mediating mechanisms have yet to be fully dissected, thereby mitigating the development of effective therapies. 2, 3, 31 We demonstrate here that ischemia-induced angiogenesis was significantly impaired by the actions of RAGE ligand AGEs and RAGE, especially in DM, and the mechanism in WT mice likely involves multiple factors, including reduced expression of inflammatory mediators, such as Egr1 and Ccl2, that recruit myeloid cells into perturbed tissues, decreased inflammatory macrophage content in ischemic muscles, and downregulation of ischemic muscle matrix metalloproteinases and growth and repair factors. Compared with WT mice undergoing FAL, mice devoid of Ager or mice overexpressing Glo1 displayed restoration of adaptive inflammatory and angiogenic responses to hindlimb ischemia.
Previous studies linked AGEs and RAGE to impairment of angiogenesis in DM but did not elucidate the underlying mechanisms. [32] [33] [34] Inhibition of AGE formation by aminoguanidine-an inhibitor of AGE-improved angiographic score, capillary density, laser Doppler skin-perfusion ratios, and restored matrix degradation processes in diabetic mice subjected to hindlimb ischemia. 32 Blockade of AGE-RAGE by adenovirus-induced overexpression of soluble RAGE-a decoy RAGE-and deficiency of Ager restored diabetesinduced impairment of angiogenesis in a matrigel patch model. 33 In addition, intramuscular administration of soluble RAGE improved angiogenic responses to hindlimb ischemia in diabetic mice. 34 It is important to note that testing the effects of soluble RAGE does not directly point to RAGEdependent mechanisms because roles for non-RAGE receptors for the families of RAGE ligands are not ruled out solely by ligand sequestration. Therefore, studies using mice genetically deficient in Ager are essential to definitively assign a critical role for RAGE activation in diabetes-and ischemiainduced impaired angiogenesis and to pinpoint underlying mechanisms.
In the present study, we demonstrated the increased expression of CML-AGE and RAGE in the hindlimb ischemic versus sham muscles, in both the nondiabetic and diabetic states, 5 days post-FAL (Figure 3 ). This work adds to the body of evidence that even in the absence of DM, ischemia increases AGE formation, shown previously in the heart. 35 Recently, it was reported that mice devoid of Ager displayed improved angiogenesis after hindlimb ischemia and that 21 days post-FAL, levels of CML-AGE in the muscles were higher in DM but not lower in the Ager −/− mice (nonischemic tissues were not tested), whereas levels of RAGE ligand HMGB1 (highmobility group box 1) were higher in ischemic versus nonischemic muscle but not affected by deletion of Ager. 36 In that work, however, genetically-modified mice or distinct liganddirected strategies were not used to probe the potential mechanistic roles of CML-AGE or HMGB1 in hindlimb ischemia.
The present experiments, in contrast, addressed mechanistic roles for AGEs in this setting. Given their roles in AGE formation and accumulation, GLO1 and methylglyoxal have been implicated in the pathogenesis of diabetic complications. 8, [37] [38] [39] Several lines of experimental evidence indicate beneficial impact of overexpression of Glo1 in animal models in DM. [40] [41] [42] [43] Overexpression of Glo1 in Caenorhabditis elegans decreased hyperglycemia-induced accumulation of AGEs and oxidative stress and enhanced lifespan. 40 Transgenic rats overexpressing human Glo1 decreased methylglyoxal-derived AGE formation and reduced retinal, neuroglial, and vascular pathology in DM and were resistant to renal ischemia-reperfusion injury. 41, 42 Overexpression of Glo1 in bone marrow cells in mice restored neovascularization to ischemic hind limbs in DM. 43 In the present study, we identified the mechanism by which Glo1 exerted its beneficial effects. First, however, we confirmed that in our model, overexpression of Glo1 in mice prevented diabetes-induced increased levels of CML-AGE modified proteins (Figure 3) . Further, we demonstrated that Glo1 prevented increases in CML-AGE modified proteins in ischemia, confirming that Glo1 plays an important role in the suppression of AGE formation in the vessel wall not only in DM, but also in ischemic injury. Second, consistent with our previous observation linking RAGE to downregulation of Glo1 in the diabetic kidney, 38 we discovered that Ager deficiency leads to higher levels of Glo1 mRNA in the skeletal muscle tissue after hindlimb ischemia in both nondiabetic and diabetic mice, whereas levels of Glo1 mRNA were suppressed by RAGE in WT mice after hindlimb ischemia. Although we did not find differences in GLO1 protein levels among WT and Ager-modified mice, we did note overall trends to lower levels of GLO1 in the respective sham versus FAL mice. Recent evidence suggests regulation of Glo1 by oxidative stressrelated pathways, such as NRF (nuclear respiratory factor 1) 44 ; whether and to what extent levels of GLO1 protein may be modulated in a high oxidative/inflammatory environment requires further study. Third, we provided evidence that transgenic (Glo1) mice reversed diabetes-and ischemia-induced impaired regulation of inflammatory mediators, Egr1 and Ccl2 and angiogenic responses to hindlimb ischemia in both nondiabetic and diabetic states. Taken together, these data link RAGE ligand AGEs to impaired inflammatory and angiogenic responses in hindlimb ischemia and suggest that upregulation of the Glo1 pathway may provide a complementary therapeutic target in the prevention of diabetic vascular damage.
Inflammatory cell infiltration early after ischemia is an important trigger for the angiogenic response to tissue ischemia. Impaired muscle regeneration in Ccl2 −/− mice suggests an important role for macrophages and MCP1 in tissuereparative processes. 45 Consistent with the implications of the current findings, Ccl2 −/− mice displayed decreased angiogenesis and reduced blood flow recovery after hindlimb ischemia versus WT mice. 45 Furthermore, it was earlier reported that mice devoid of Egr1 (nondiabetic state) displayed reduced numbers of regenerating arterioles after FAL. 46 In both studies, however, the effect of deletion of Egr1 or Ccl2 on inflammatory mechanisms in the ischemic tissue was not explored. Here, we demonstrate that RAGE-dependent mechanisms mediate regulation of these 2 key factors in the ischemic hindlimb. In contrast to these findings in FAL and hindlimb ischemia, in hyperlipidemic mice, deletion of either Egr1 or Ccl2 is atheroprotective. 47, 48 What might begin to explain these apparent conflicting findings?
Our data unveil the intriguing finding that RAGE plays opposing roles in regulating Egr1 and Ccl2 expression in acute versus chronic hypoxia/ischemia because when Ager is deleted in hindlimb ischemia, higher macrophage content in the ischemic muscle ensues-and is linked to repair-distinct from that observed in chronic atherosclerosis and acute hypoxia in mouse hearts in which Ager deletion significantly reduced Egr1 and Ccl2 transcripts and lesional macrophage content in vascular tissues. 17, 49, 50 Because differences in circulating levels of MCP1 did not explain the benefits of Ager deletion in hindlimb ischemia, we turned to examination of peripheral monocytes and neutrophils in these mice because our data revealed that muscle tissue levels of CD68+ macrophages were significantly higher in nondiabetic or diabetic Ager −/− mice versus respective WT mice after FAL. These endeavors uncovered the surprising finding that higher Ly6C hi monocytes were found in diabetic versus nondiabetic mice of both the WT and Ager −/− genotypes ( Figure 6 ). In atherosclerosis, this subset of Ly6C hi monocytes facilitates atherosclerosis; in contrast, the present work implicates these cells in tissue repair. 51, 52 Here, in hindlimb ischemia, we surmise that the local environment, at least in part, driven by RAGE, recruits tissue-reparative cells driven by early but transient upregulation of Egr1 and Ccl2. Critically, in all mouse groups, by day 28 post-FAL, muscle tissue levels of these factors were dramatically lower and did not greatly differ by genotype postischemia ( Figure I in the online-only Data Supplement).
Examination of the PCR array data (Tables II, III , and IV in the online-only Data Supplement) supports the paradigm that in hindlimb ischemia, particularly in DM, RAGE blunts a proinflammatory microenvironment needed for tissue repair. In contrast, both nondiabetic or diabetic mice devoid of Ager display higher levels of several chemokines and their ligands, particularly Ccl2 in the ischemic muscle tissue, compared with their WT counterparts. CCL2/MCP1 are ligands for Ly6C hi cells, [53] [54] [55] thereby contributing to the higher number of macrophages infiltrating the ischemic muscle tissue on day 7 in the Ager −/− versus WT mice ( Figure 2C ; Tables II, III , and IV in the online-only Data Supplement). Interestingly, although levels of Il1b were significantly higher in nondiabetic or diabetic Ager −/− ischemic muscle versus respective WT counterparts on day 5 post-FAL, these levels were much lower in the mice devoid of Ager by day 7, relative to the WT. In parallel, levels of Thbs1 (latent activator of Tgfb1) 56 were significantly higher in Ager −/− ischemic tissue by day 7 post-FAL and by 7, significantly higher levels of tissue-reparative Tgfb1, as well as Angpt2, Hgf, and Pgf, were evident in ischemic tissue devoid of Ager versus the respective WT mice in the nondiabetic and diabetic states. These data mirror the improvement in angiogenesis and blood flow recovery observed in the Ager −/− versus WT mice in both the diabetic and nondiabetic states and reflect the overall patterns that were observed in isolated BMDMs. In BMDMs devoid of Ager, lower levels of M1 like proinflammatory cytokines and higher levels of M2 like molecules linked to tissue repair (Arg1 and Il10) were observed in HG conditions ( Figure III in the onlineonly Data Supplement). Interestingly, levels of Vegf a, b, and c were not significantly modulated in FAL in the nondiabetic or diabetic ischemic muscles of WT or Ager −/− mice, but levels of other factors, such as Thbs1 and Tgfb1, were significantly affected by DM and deletion of Ager. Our findings on the lack of RAGE-dependent effects on Vegf are intriguing and warrant further analyses; it is notable, however, that studies of others in cultured bone marrow cells from 12 months diabetic or nondiabetic mice failed to demonstrate differences in the production of VEGF (vascular endothelial growth factor) protein. 57 In vitro studies also supported inflammatory roles for RAGE in macrophages, as we demonstrated that macrophages grown in HG displayed decreased functional potential; that is, these macrophages demonstrated reduced adhesion to WT murine endothelial cells compared with WT macrophages grown in physiological levels of glucose in a RAGE-dependent manner ( Figure 6A ). Critically, our study also uncovered that simply deleting Ager in murine endothelial cells did not rescue the suppressive effects of HG on impaired WT macrophage adherence. Rather, only when Ager was deleted either in macrophages alone or in both macrophages and endothelial cells was the reduced adhesion of macrophages to endothelial cells in HG rescued. In future studies, it would, thus, be useful to determine how conditions mimicking the hyperlipidemic environment might affect macrophage-endothelial adhesion vis-à-vis the RAGE axis. It is notable that Babu et al 58 tested the impact of hyperlipidemia versus hyperglycemia (type 2 DM) stresses on ischemic muscle macrophages isolated 7 days post-FAL. Differential promoter methylation studies revealed that in both settings, significant promoter hypomethylation (increased transcription) of prototypic M1 macrophages) and hypermethylation (reduced transcription) of anti-inflammatory and proangiogenic M2 macrophages was evident when compared with the WT control mice. Of note, however, the genes altered by hyperlipidemia versus hyperglycemia were not fully overlapping, suggesting that further in-depth probing of these datasets might uncover factors exhibiting differential responses to these metabolic perturbations.
It is not surprising that the immune/inflammatory system was designed to establish multiple checkpoints to protect against imbalances in pro-versus anti-inflammatory forces. In the case of the toll receptor family, for example, it was shown that extensive cross-talk between Tlr4 and Tlr2 is required in mediating adaptive responses to hindlimb ischemia, when tested in nondiabetic mice. 59, 60 The present work adds RAGE to the cadre of genes that exhibit tissue microenvironmentdependent roles in inflammation and tissue regeneration. In this context, a burgeoning body of evidence links RAGE to opposing outcomes in murine models of infection challenge. For example, whereas deletion of Ager in Streptococcus pneumoniae pneumonia or Acinetobacter baumanii sepsis resulted in improved survival and diminished tissue damage, 61, 62 Ager deletion in a distinct setting of Klebsiella pneumoniae was detrimental to survival and recovery. 63 These considerations underscore the complexities of RAGE in the immune and vascular response to imposed stresses.
Taken together, the present work suggests unique hypoxia/ ischemia-dependent mechanisms in hindlimb ischemia that may be rescued by deletion of Ager and by specific means to reduce AGE burden. This work underscores the premise that RAGE may dampen tissue-reparative inflammation in hindlimb ischemia, thereby blocking adaptive angiogenesis and restoration of blood flow. We conclude that deletion of Ager resets adaptive inflammatory cues in a tissue microenvironment-sensitive manner and surmise that antagonism of RAGE might fill a key therapeutic gap in peripheral arterial disease, particularly in DM.
